BioNTech SE (NASDAQ:BNTX) is a biotechnology company known for its pioneering work in mRNA technology, particularly its role in developing a COVID-19 vaccine. The company is now focusing on oncology, with plans to have 15 ongoing Phase 3 trials by the end of 2026. BioNTech's co-founders, Ugur Sahin and Özlem Türeci, are launching a new biotech venture, which has impacted the company's stock performance.
On March 10, 2026, Morgan Stanley set a price target of $128 for BioNTech, suggesting a potential increase of 52.58% from its current trading price of $83.89. This optimistic outlook comes despite recent challenges, including a 21% drop in share price following the announcement of the co-founders' departure. The stock has fluctuated between $79.52 and $85.50 yesterday, with a market cap of $20.17 billion.
BioNTech's strategic shift towards oncology is significant, as the company aims to maximize value for patients and shareholders. Despite reporting a net loss of €1.14 billion ($1.33 billion) for 2025, BioNTech ended the year with €17.2 billion in cash and financial securities. This financial stability supports its ongoing and future clinical trials, which are crucial for its growth in the oncology sector.
The new venture by BioNTech's co-founders will focus on next-generation mRNA technologies, allowing both companies to concentrate on their respective priorities. BioNTech's Supervisory Board is actively searching for successors to lead the company as it continues its oncology efforts. The co-founders' transition is expected by the end of 2026, marking a new chapter for BioNTech and its strategic direction.
Despite recent losses, BioNTech's financial position remains strong, with a better-than-expected fourth-quarter loss of 38 cents. The company's focus on oncology and the potential of its new venture in mRNA technology could drive future growth. As BioNTech navigates these changes, the market will closely watch its progress in clinical trials and leadership transitions.
